---
cssClass:
- wide
---

# `Title:` [[Targeting RNA]]
--- 

- What led me here: [[Drug Therapies]]

Inlinks
```dataview 
list from [[#this.file.name]] and !outgoing([[# this.file.name]]) 
```
![[03_Bayer_Infografik_RNA_targeting_620x349.jpeg]]

# Targeting RNA with Small Molecules to Treat Diseases

RNA has emerged as a significant target for the development of therapeutic agents to treat a variety of diseases. The traditional focus on proteins as drug targets has shifted in recent years due to a deeper understanding of RNA's crucial roles in gene regulation and expression, as well as its involvement in disease pathogenesis. This article provides an overview of the approaches used to target RNA with small molecules, highlighting their therapeutic potential, advantages, and limitations.

## Importance of RNA as a Drug Target

RNA's versatility in function and its involvement in critical cellular processes make it an attractive target for drug development. Recent advances in RNA biology have uncovered its pivotal roles in multiple disease states, including viral and bacterial infections, cancer, and neurological disorders ([Shao](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724634/); [Falese](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018613/)). The ability to modulate RNA function with small molecules offers a novel strategy to combat these diseases.

## Approaches to Targeting RNA

### RNA Structure-Based Drug Design

The three-dimensional structures of RNA present unique challenges and opportunities for drug design. Unlike proteins, RNA structures are less diverse, but they form complex secondary and tertiary structures that can be specifically targeted by small molecules. Drug-like molecules that can selectively bind to these structures have the potential to modulate RNA function in a disease context ([Shao](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724634/)).

### High-Throughput Screening

High-throughput screening (HTS) of small molecule libraries against RNA targets has become an essential tool in identifying potential RNA-binding compounds. By screening large libraries of compounds, researchers can quickly identify molecules that exhibit selective binding to RNA structures of interest ([Shao](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724634/)).

### Rational Design and Computational Approaches

Computational methods and rational design approaches have advanced the field of RNA-targeted drug discovery. These methods leverage the structural information of RNA to design molecules with high affinity and specificity. Computational chemistry tools can predict how small molecules interact with RNA structures, guiding the synthesis of potential therapeutics ([in-text citation](https://app.tavily.com/url)).

### Chemical Probing and Mapping

Chemical probing techniques provide insights into RNA structure and dynamics, which are crucial for understanding how small molecules interact with RNA. Mapping the accessible regions of RNA allows for the identification of potential binding sites for small molecules ([in-text citation](https://app.tavily.com/url)).

## Clinical Applications and Success Stories

Several small molecules targeting RNA have shown promise in clinical settings. For example, drugs targeting ribosomal RNA have been successful in treating bacterial infections, and molecules targeting viral RNA have been effective against influenza and hepatitis C virus ([Falese](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018613/)). Additionally, small molecule drugs treating spinal muscular atrophy (SMA) have reached clinical trials, demonstrating the therapeutic potential of RNA-targeting strategies ([in-text citation](https://app.tavily.com/url)).

## Challenges and Future Directions

Despite the promise of RNA-targeted therapeutics, several challenges remain. The selectivity and specificity of small molecule-RNA interactions are critical for therapeutic efficacy and safety. The development of RNA-biased small molecule libraries and the fundamental understanding of RNA-small molecule interactions are areas of ongoing research ([in-text citation](https://app.tavily.com/url)). Moreover, the delivery of RNA-targeted drugs to specific tissues or cells in the body remains a significant hurdle.

The future of RNA-targeted drug discovery is bright, with continued advancements in understanding RNA biology and structure, as well as improvements in drug design and screening methodologies. The development of more selective and potent RNA-binding small molecules could revolutionize the treatment of diseases that are currently difficult to manage with existing therapies.

## Conclusion

Targeting RNA with small molecules represents a frontier in the development of novel therapeutics for a range of diseases. The unique properties of RNA structures provide opportunities for selective drug targeting, which can lead to the development of highly specific and effective treatments. While challenges remain, the advances in RNA biology, drug design, and computational approaches are paving the way for the next generation of RNA-targeted therapies.

## References

Shao, Yanqiu. "Targeting RNA structures in diseases with small molecules." _Biochemical Society Transactions_, vol. 64, no. 6, 2020, pp. 955-966, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724634/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724634/).

Falese, James P. "Targeting RNA with small molecules: from fundamental principles towards the clinic." _Chemical Society Reviews_, 2021, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018613/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018613/).

"Targeting RNA with small molecules: from fundamental principles towards the clinic." _Chemical Society Reviews_, 2021, [https://pubs.rsc.org/en/content/articlelanding/2021/cs/d0cs01261k](https://pubs.rsc.org/en/content/articlelanding/2021/cs/d0cs01261k).

"Targeting RNA with small molecules." _Chemical Communications_, 2020, [https://pubs.rsc.org/en/content/articlehtml/2020/cc/d0cc06796b](https://pubs.rsc.org/en/content/articlehtml/2020/cc/d0cc06796b).

"Assessing RNA as a Drug Target." _National Center for Biotechnology Information_, 2020, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486258/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486258/).